Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graves Ophthalmopathy | 2 | 2022 | 10 | 0.910 |
Why?
|
| Exophthalmos | 2 | 2022 | 18 | 0.910 |
Why?
|
| Eyelid Diseases | 2 | 2022 | 19 | 0.890 |
Why?
|
| Drug Costs | 2 | 2016 | 106 | 0.890 |
Why?
|
| Eye Diseases | 3 | 2021 | 87 | 0.800 |
Why?
|
| Health Care Costs | 2 | 2016 | 398 | 0.740 |
Why?
|
| Ophthalmologists | 2 | 2020 | 12 | 0.680 |
Why?
|
| Methotrexate | 2 | 2016 | 260 | 0.580 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2016 | 1313 | 0.580 |
Why?
|
| Hemifacial Spasm | 1 | 2018 | 2 | 0.570 |
Why?
|
| Blepharospasm | 1 | 2018 | 7 | 0.570 |
Why?
|
| Botulinum Toxins | 1 | 2018 | 41 | 0.540 |
Why?
|
| Behcet Syndrome | 1 | 2016 | 18 | 0.520 |
Why?
|
| Rheumatologists | 1 | 2016 | 16 | 0.520 |
Why?
|
| Azathioprine | 1 | 2016 | 54 | 0.510 |
Why?
|
| Insurance, Health | 2 | 2016 | 283 | 0.490 |
Why?
|
| Arthritis, Juvenile | 1 | 2016 | 56 | 0.480 |
Why?
|
| Vision Disorders | 1 | 2016 | 142 | 0.460 |
Why?
|
| Glucocorticoids | 2 | 2016 | 594 | 0.460 |
Why?
|
| Uveitis | 1 | 2016 | 136 | 0.460 |
Why?
|
| Uveitis, Posterior | 1 | 2014 | 12 | 0.450 |
Why?
|
| Uveitis, Intermediate | 1 | 2014 | 8 | 0.450 |
Why?
|
| Eyelid Neoplasms | 2 | 2024 | 10 | 0.410 |
Why?
|
| Ophthalmology | 3 | 2020 | 86 | 0.260 |
Why?
|
| Corneal Diseases | 1 | 2025 | 35 | 0.230 |
Why?
|
| Specialization | 2 | 2016 | 144 | 0.220 |
Why?
|
| Cornea | 1 | 2025 | 138 | 0.220 |
Why?
|
| Mohs Surgery | 1 | 2024 | 27 | 0.210 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2024 | 75 | 0.200 |
Why?
|
| Eye Hemorrhage | 1 | 2022 | 2 | 0.200 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2022 | 2 | 0.200 |
Why?
|
| Visual Acuity | 1 | 2025 | 356 | 0.200 |
Why?
|
| Surgical Flaps | 1 | 2024 | 130 | 0.200 |
Why?
|
| Electronic Health Records | 2 | 2020 | 1069 | 0.190 |
Why?
|
| Blepharitis | 1 | 2022 | 5 | 0.190 |
Why?
|
| Keratitis | 1 | 2022 | 15 | 0.190 |
Why?
|
| Ophthalmoplegia | 1 | 2021 | 8 | 0.180 |
Why?
|
| Trochlear Nerve Diseases | 1 | 2021 | 7 | 0.180 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 1 | 2021 | 9 | 0.180 |
Why?
|
| Cavernous Sinus | 1 | 2021 | 19 | 0.180 |
Why?
|
| Immunosuppressive Agents | 2 | 2016 | 890 | 0.180 |
Why?
|
| Mucormycosis | 1 | 2021 | 22 | 0.180 |
Why?
|
| Population Health | 1 | 2021 | 47 | 0.170 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 5778 | 0.170 |
Why?
|
| Orbital Diseases | 1 | 2021 | 32 | 0.170 |
Why?
|
| Coinfection | 1 | 2021 | 137 | 0.160 |
Why?
|
| Decision Making | 2 | 2016 | 900 | 0.140 |
Why?
|
| Triage | 1 | 2020 | 222 | 0.140 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 267 | 0.140 |
Why?
|
| Injections | 1 | 2018 | 183 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 565 | 0.130 |
Why?
|
| Administration, Topical | 1 | 2016 | 151 | 0.130 |
Why?
|
| Humans | 16 | 2025 | 137585 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 804 | 0.120 |
Why?
|
| Rheumatology | 1 | 2016 | 118 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2020 | 786 | 0.110 |
Why?
|
| Health Care Surveys | 1 | 2016 | 565 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 855 | 0.110 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 322 | 0.100 |
Why?
|
| Quality of Life | 1 | 2025 | 2892 | 0.100 |
Why?
|
| Health Surveys | 1 | 2014 | 514 | 0.100 |
Why?
|
| Patient Selection | 1 | 2016 | 696 | 0.100 |
Why?
|
| Female | 7 | 2025 | 73304 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2016 | 631 | 0.090 |
Why?
|
| Middle Aged | 4 | 2025 | 33479 | 0.090 |
Why?
|
| United States | 3 | 2021 | 14841 | 0.090 |
Why?
|
| Retrospective Studies | 3 | 2024 | 15657 | 0.080 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 5472 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 2069 | 0.070 |
Why?
|
| Adult | 3 | 2025 | 37929 | 0.070 |
Why?
|
| Patient Satisfaction | 2 | 2024 | 660 | 0.070 |
Why?
|
| Male | 5 | 2025 | 67762 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2020 | 7604 | 0.070 |
Why?
|
| Blepharoplasty | 1 | 2024 | 10 | 0.050 |
Why?
|
| Eyelids | 1 | 2024 | 37 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 24 | 0.050 |
Why?
|
| Oculomotor Muscles | 1 | 2022 | 40 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 7635 | 0.050 |
Why?
|
| Adolescent | 1 | 2021 | 21513 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2022 | 317 | 0.040 |
Why?
|
| Invasive Fungal Infections | 1 | 2021 | 11 | 0.040 |
Why?
|
| Ketosis | 1 | 2021 | 12 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2022 | 157 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2021 | 303 | 0.040 |
Why?
|
| Aged | 3 | 2025 | 23961 | 0.040 |
Why?
|
| Telephone | 1 | 2020 | 173 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 422 | 0.040 |
Why?
|
| Sinusitis | 1 | 2021 | 221 | 0.040 |
Why?
|
| Documentation | 1 | 2020 | 194 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 722 | 0.030 |
Why?
|
| Child | 1 | 2016 | 21935 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 1276 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2020 | 1118 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 3284 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2691 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 10811 | 0.020 |
Why?
|